Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice

Walker, Emma C., McGregor, Narelle E., Poulton, Ingrid J., Solano, Melissa, Pompolo, Sueli, Fernandes, Tania J., Constable, Matthew J., Nicholson, Geoff C., Zhang, Jian-Guo, Nicola, Nicos A., Gillespie, Matthew T., Martin, T. John and Sims, Natalie A. (2010) Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. Journal of Clinical Investigation, 120 2: 582-592. doi:10.1172/JCI40568


Author Walker, Emma C.
McGregor, Narelle E.
Poulton, Ingrid J.
Solano, Melissa
Pompolo, Sueli
Fernandes, Tania J.
Constable, Matthew J.
Nicholson, Geoff C.
Zhang, Jian-Guo
Nicola, Nicos A.
Gillespie, Matthew T.
Martin, T. John
Sims, Natalie A.
Title Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice
Journal name Journal of Clinical Investigation   Check publisher's open access policy
ISSN 0021-9738
1558-8238
Publication date 2010-02
Sub-type Article (original research)
DOI 10.1172/JCI40568
Open Access Status DOI
Volume 120
Issue 2
Start page 582
End page 592
Total pages 11
Place of publication Ann Arbor, MI, United States
Publisher American Society for Clinical Investigation
Language eng
Abstract Effective osteoporosis therapy requires agents that increase the amount and/or quality of bone. Any modification of osteoclast-mediated bone resorption by disease or drug treatment, however, elicits a parallel change in osteoblast-mediated bone formation because the processes are tightly coupled. Anabolic approaches now focus on uncoupling osteoblast action from osteoclast formation, for example, by inhibiting sclerostin, an inhibitor of bone formation that does not influence osteoclast differentiation. Here, we report that oncostatin M (OSM) is produced by osteoblasts and osteocytes in mouse bone and that it has distinct effects when acting through 2 different receptors, OSM receptor (OSMR) and leukemia inhibitory factor receptor (LIFR). Specifically, mouse OSM (mOSM) inhibited sclerostin production in a stromal cell line and in primary murine osteoblast cultures by acting through LIFR. In contrast, when acting through OSMR, mOSM stimulated RANKL production and osteoclast formation. A key role for OSMR in bone turnover was confirmed by the osteopetrotic phenotype of mice lacking OSMR. Furthermore, in contrast to the accepted model, in which mOSM acts only through OSMR, mOSM inhibited sclerostin expression in Osmr-/- osteoblasts and enhanced bone formation in vivo. These data reveal what we believe to be a novel pathway by which bone formation can be stimulated independently of bone resorption and provide new insights into OSMR and LIFR signaling that are relevant to other medical conditions, including cardiovascular and neurodegenerative diseases and cancer.
Keyword Kappa-b Ligand
In-vitro
M OSM
Osteoclast Differentiation
Targeted Disruption
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 72 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 79 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 May 2011, 15:06:18 EST by System User on behalf of School of Medicine